DGAP-News: Sangui BioTech International Inc. / Key word(s): 9 Month figures 
Sangui BioTech International Inc.: - Significant increase in sales in the first nine months - Reduction of operating 
loss 
2021-05-10 / 12:19 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
 
Sangui BioTech: 
- Significant increase in sales in the first nine months 
- Reduction of operating loss 
 
Hamburg, May, 10 2021: In the first nine month of fiscal year 2021 (to 30/06/2021) Sangui BioTech International Inc. 
achieved revenues from royalty income of USD 51,754. In the same period of the previous year the comparable revenue 
amounted to USD 21,176. Due to higher revenues of the wound spray Granulox, the resulting royalty income in the first 
nine month of the year was above the level of the same period of the previous year. 
Operating expenses increased USD 11,731 or 8% to USD 162,793 during the first three quarters. As a result of the above 
factors, the nine month operating loss decreased USD 18,847 to USD 111,039. Due to the lower exchange rate of the US 
dollar to the EURO compared to the previous year's reporting date and the resulting increased exchange rate loss from 
the valuation of loans denominated in EURO, the loss of the nine month period increased by USD 24,513 to USD 151,923. 
Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB 
venture stage marketplace for early stage and developing U.S. and international companies (OTCQB: SGBI). Companies are 
current in their reporting and undergo an annual verification and management certification process. Sangui shares also 
trade on the OTC markets of Berlin and Hamburg-Hannover stock exchanges (symbol: SBH). Its purpose is to provide 
financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety 
percent subsidiary of Sangui BioTech International, Inc. 
For more information please contact: 
Sangui Biotech International, Inc. 
Thomas Striepe 
e-mail: info@sangui.de 
Some of the statements contained in this news release discuss future expectations, contain projections of results of 
operation or financial condition or state other "forward-looking" information. These statements are subject to known 
and unknown risks, uncertainties, and other factors that could cause the actual results to differ materially from those 
contemplated by the statements. The forward-looking information is based on various factors and is derived using 
numerous assumptions. Important factors that may cause actual results to differ from projections include, among many 
others, the ability of the Company to raise sufficient capital to meet operating requirements. Words such as 
"anticipates," "expects," "intends," "plans," "believes," "seeks," "estimates," and variations of such words and 
similar expressions are intended to identify such forward-looking statements. Unless required by law, the Company 
undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, 
future events or otherwise. 
=---------------------------------------------------------------------------------------------------------------------- 
2021-05-10 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
=----------------------------------------------------------------------------------------------------------------------

1194544 2021-05-10


 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1194544&application_name=news

(END) Dow Jones Newswires

May 10, 2021 06:20 ET (10:20 GMT)